Table 1. Baseline Characteristics of Patients.
| Characteristics | Recombinant Human Pentraxin 2 (n = 77) | Placebo (n = 39) |
|---|---|---|
| Male sex, No. (%) | 65 (84) | 29 (74) |
| Age, mean (SD), y | 69.0 (6.3) | 67.6 (7.1) |
| Weight, mean (SD), kg | 86.1 (15.2) | 87.5 (13.4) |
| Time since diagnosis of IPF | ||
| Mean (SD), y | 3.7 (2.2) | 3.9 (2.6) |
| Median (IQR), y | 3.0 (2.0-5.0) | 3.0 (2.0-4.0) |
| FVC | ||
| Mean (SD), mL | 2733 (630) | 2763 (654) |
| Median (IQR), mL | 2700 (2320-3140) | 2610 (2290-3250) |
| Percentage of predicted value, mean (SD) | 67.7 (10.9) | 67.4 (11.4) |
| FEV1/FVC, mean (SD), % | 81.2 (5.1) | 81.6 (4.7) |
| Hemoglobin-corrected Dlco, % of predicted values, mean (SD) | 40.1 (9.14) | 43.2 (10.5) |
| 6-min walk test distance | ||
| Mean (SD), m | 434.8 (92.5) | 457.7 (117.7) |
| Median (IQR), m | 436.0 (368.0-494.0) | 450.0 (370.0-535.0) |
| SpO2 at rest, mean (SD), % | 95.6 (2.1) | 95.5 (1.8) |
| Patients with SpO2 at rest <95%, No. (%) | 20 (26) | 9 (23) |
| IPF therapy status at baseline, No. (%) | ||
| Concurrent IPF therapy | 61 (79) | 30 (77) |
| Pirfenidone | 39 (64) | 22 (73) |
| Nintedanib | 22 (36) | 8 (27) |
| No concurrent IPF therapy | 16 (21) | 9 (23) |
| IPF therapy naive | 8 (10) | 7 (18) |
| Baseline pentraxin 2 concentrations | ||
| Mean (SD), ng/mL | 30 456 (13 567) | 30 962 (10 090) |
| Median (IQR), ng/mL | 29 500 (23 500-38 750) | 29 500 (26 250-33 500) |
| Comorbid conditions | ||
| GERD | 47 (61) | 16 (41) |
| Hypertension | 38 (49) | 14 (35) |
| Cardiac disorders | 29 (38) | 7 (18) |
| Coronary artery disorders | 15 (19) | 4 (10) |
| Emphysema | 2 (3) | 0 |
| Pulmonary hypertension | 1 (1) | 3 (8) |
Abbreviations: Dlco, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; SpO2, oxygen saturation of peripheral blood.